CD82 Recombinant monoclonal antibody, PBS Only 84617-3-PBS proteintech

$699.00
In stock
SKU
84617-3-PBS
Catalog No.SizePrice (USD)
84617-3-PBS-100UG100 μg$699.00
Catalog Number84617-3-PBS
SynonymsCD82, KAI1, 241765E10, CD 82, CD82,KAI1, IA4
HostRabbit
Reactivityhuman
FormLiquid
FormulationPBS Only
ApplicationsIF/ICC, Indirect ELISA
Host / IsotypeRabbit / IgG
Tested Reactivityhuman
ClassRecombinant
TypeAntibody
ImmunogenCatNo: Eg1749 Product name: Recombinant Human CD82 protein (rFc Tag) (HPLC verified) Source: mammalian cells -derived, pHZ-KIsec-C-rFc Tag: C-rFc Domain: 111-228 aa of NM_002231.4 Sequence: GKLKQEMGGIVTELIRDYNSSREDSLQDAWDYVQAQVKCCGWVSFYNWTDNAELMNRPEVTYPCSCEVKGEEDNSLSVRKGFCEAPGNRTQSGNHPEDWPVYQEGCMEKVQAWLQENL Predict reactive species
Full NameCD82 molecule
Calculated Molecular Weight30 kDa
GenBank Accession NumberNM_002231.4
Gene SymbolCD82
Gene ID (NCBI)3732
RRIDAB_3743612
ConjugateUnconjugated
Purification MethodProtein A purification
UNIPROT IDP27701-1
Storage BufferPBS only, pH 7.3.
Storage ConditionsStore at -80°C.
Citations-
IsotypeIgG
ClonalityRecombinant
Clone Number241765E10
ConjugationUnconjugated

CD82 is a membrane glycoprotein and belongs to the tetraspanin superfamily, many of which are implicated in the regulation of cell motility, morphology, fusion, signaling, fertilization, and differentiation. CD82 was originally identified as a suppressor of metastasis located on human chromosome 11p11.2 in prostate carcinoma. The majority of evidence indicates that CD82 expression is downregulated or abolished in a variety of malignant tumors. CD82 is present at high levels in human monocyte and macrophage lineages and in various epithelial cells in the prostate, lung, pancreas and many other tissues. In epithelial cells, CD82 is implicated in diverse biological processes such as cell adhesion, migration, apoptosis and morphogenesis.

Reviews

Write Your Own Review
You're reviewing:CD82 Recombinant monoclonal antibody, PBS Only 84617-3-PBS proteintech
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.